Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Consumer & Luxury

The Final Chapter for Hanesbrands as a Public Company

Andreas Sommer by Andreas Sommer
December 2, 2025
in Consumer & Luxury, Market Commentary, Mergers & Acquisitions
0
Hanesbrands Stock
0
SHARES
75
VIEWS
Share on FacebookShare on Twitter

The independent story of Hanesbrands on the public markets has reached its conclusion. The apparel maker’s acquisition by Canadian competitor Gildan Activewear, valued at approximately $2.2 billion, was finalized, leading to the cessation of its stock listing on the New York Stock Exchange effective December 1, 2025.

Shareholder Compensation and New Ownership

Remaining equity holders received a definitive exchange offer. For each share of Hanesbrands they owned, investors were granted $0.80 in cash plus 0.102 shares of the acquiring firm, Gildan. This transaction results in former Hanesbrands shareholders collectively owning an estimated 19.9% stake in the newly combined entity. The investment narrative for Hanesbrands as a standalone stock is now closed.

Full Market Exit and Delisting Process

The withdrawal from public trading is comprehensive. Concurrent with the halt in stock trading, the company was removed from all options exchanges within the MIAX Exchange Group, including MIAX Options and MIAX Pearl. The official delisting was executed through the filing of a Form 25 with the U.S. Securities and Exchange Commission (SEC), eliminating all remaining liquidity for the security.

Should investors sell immediately? Or is it worth buying Hanesbrands?

Strategic Ambitions of a Combined Powerhouse

The merger creates a dominant force in the basic apparel sector. The unified company is projected to generate annual revenue of roughly $6.9 billion, effectively doubling Gildan’s previous scale. Management is targeting significant synergies from the deal:

  • Annual cost savings of at least $200 million, to be realized within a three-year timeframe.
  • Analysts at Stifel Bank project an 18% boost to earnings per share (EPS accretion) in the first year following the merger.
  • Long-term, this positive earnings impact could potentially reach up to 40% as synergies are fully realized.

The strategic focus is firmly on expanding the Hanes underwear business. As the corporate headquarters in Winston-Salem faces an uncertain future regarding its structure, Gildan is integrating the acquired brands and distribution networks into its global strategy. Market attention now shifts entirely to Gildan’s stock.

Ad

Hanesbrands Stock: Buy or Sell?! New Hanesbrands Analysis from February 7 delivers the answer:

The latest Hanesbrands figures speak for themselves: Urgent action needed for Hanesbrands investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Hanesbrands: Buy or sell? Read more here...

Tags: Hanesbrands
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Carrefour PK Stock

Carrefour Completes Strategic Exit from Italy

QuantumScape Stock

Insider Selling and Analyst Downgrades Cloud QuantumScape's Outlook

Encore Wire Stock

Prysmian's Strategic US Investment Earns Top Transatlantic Honor

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com